General Information of Drug Off-Target (DOT) (ID: OTMKF1O3)

DOT Name DNA-directed RNA polymerase II subunit RPB11-a (POLR2J)
Synonyms RNA polymerase II subunit B11-a; RPB11a; DNA-directed RNA polymerase II subunit J-1; RNA polymerase II 13.3 kDa subunit
Gene Name POLR2J
Related Disease
Breast carcinoma ( )
UniProt ID
RPB11_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
5IY6; 5IY7; 5IY8; 5IY9; 5IYA; 5IYB; 5IYC; 5IYD; 6DRD; 6O9L; 6XRE; 7LBM
Pfam ID
PF13656
Sequence
MNAPPAFESFLLFEGEKKITINKDTKVPNACLFTINKEDHTLGNIIKSQLLKDPQVLFAG
YKVPHPLEHKIIIRVQTTPDYSPQEAFTNAITDLISELSLLEERFRVAIKDKQEGIE
Function
Core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates.
Tissue Specificity Ubiquitously expressed. High expression was found in heart and skeletal muscle.
KEGG Pathway
R. polymerase (hsa03020 )
Nucleotide excision repair (hsa03420 )
Huntington disease (hsa05016 )
Reactome Pathway
Formation of the Early Elongation Complex (R-HSA-113418 )
Formation of HIV elongation complex in the absence of HIV Tat (R-HSA-167152 )
Formation of the HIV-1 Early Elongation Complex (R-HSA-167158 )
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection (R-HSA-167160 )
HIV Transcription Initiation (R-HSA-167161 )
RNA Polymerase II HIV Promoter Escape (R-HSA-167162 )
Transcription of the HIV genome (R-HSA-167172 )
Formation of HIV-1 elongation complex containing HIV-1 Tat (R-HSA-167200 )
Pausing and recovery of Tat-mediated HIV elongation (R-HSA-167238 )
Abortive elongation of HIV-1 transcript in the absence of Tat (R-HSA-167242 )
Tat-mediated HIV elongation arrest and recovery (R-HSA-167243 )
Tat-mediated elongation of the HIV-1 transcript (R-HSA-167246 )
HIV elongation arrest and recovery (R-HSA-167287 )
Pausing and recovery of HIV elongation (R-HSA-167290 )
Viral Messenger RNA Synthesis (R-HSA-168325 )
MicroRNA (miRNA) biogenesis (R-HSA-203927 )
Transcriptional regulation by small RNAs (R-HSA-5578749 )
PIWI-interacting RNA (piRNA) biogenesis (R-HSA-5601884 )
Activation of anterior HOX genes in hindbrain development during early embryogenesis (R-HSA-5617472 )
RNA Polymerase II Pre-transcription Events (R-HSA-674695 )
Formation of TC-NER Pre-Incision Complex (R-HSA-6781823 )
Transcription-Coupled Nucleotide Excision Repair (TC-NER) (R-HSA-6781827 )
Dual incision in TC-NER (R-HSA-6782135 )
Gap-filling DNA repair synthesis and ligation in TC-NER (R-HSA-6782210 )
TP53 Regulates Transcription of DNA Repair Genes (R-HSA-6796648 )
FGFR2 alternative splicing (R-HSA-6803529 )
RNA polymerase II transcribes snRNA genes (R-HSA-6807505 )
mRNA Capping (R-HSA-72086 )
mRNA Splicing - Major Pathway (R-HSA-72163 )
mRNA Splicing - Minor Pathway (R-HSA-72165 )
Processing of Capped Intron-Containing Pre-mRNA (R-HSA-72203 )
RNA Polymerase II Promoter Escape (R-HSA-73776 )
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening (R-HSA-73779 )
RNA Polymerase II Transcription Initiation (R-HSA-75953 )
RNA Polymerase II Transcription Elongation (R-HSA-75955 )
RNA Polymerase II Transcription Initiation And Promoter Clearance (R-HSA-76042 )
RNA Pol II CTD phosphorylation and interaction with CE (R-HSA-77075 )
Signaling by FGFR2 IIIa TM (R-HSA-8851708 )
Estrogen-dependent gene expression (R-HSA-9018519 )
Inhibition of DNA recombination at telomere (R-HSA-9670095 )
Formation of RNA Pol II elongation complex (R-HSA-112382 )

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Breast carcinoma DIS2UE88 Strong Genetic Variation [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
5 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the expression of DNA-directed RNA polymerase II subunit RPB11-a (POLR2J). [2]
Doxorubicin DMVP5YE Approved Doxorubicin increases the expression of DNA-directed RNA polymerase II subunit RPB11-a (POLR2J). [3]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of DNA-directed RNA polymerase II subunit RPB11-a (POLR2J). [4]
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the expression of DNA-directed RNA polymerase II subunit RPB11-a (POLR2J). [5]
Milchsaure DM462BT Investigative Milchsaure decreases the expression of DNA-directed RNA polymerase II subunit RPB11-a (POLR2J). [6]
------------------------------------------------------------------------------------

References

1 Association analysis identifies 65 new breast cancer risk loci.Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.
2 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
3 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
4 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
5 Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
6 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.